Clinical efficacy analysis of bronchoalveolar lavage combined with levofloxacin in the treatment of refractory drug-resistant mycoplasma pneumoniae pneumonia in children

Background The purpose of this article is to explore the efficacy and safety of bronchoalveolar lavage with levofloxacin combined with intravenous infusion in the treatment of refractory drug-resistant mycoplasma pneumonia. Methods 120 children with refractory mycoplasma pneumoniae pneumonia (RMPP) were studied and divided into the control group (60 cases) and the observation group (60 cases) based on different treatment methods. The control group was received levofloxacin treatment and control supportive treatment, while the observation group was received bronchoscopy for alveolar lavage on the lesion side in addition to the control group, and local drug retention of levofloxacin was performed. Observe for 7 days after treatment and compare the improvement of clinical symptoms, C-reactive protein (CRP), serum ferritin (SF), lactate dehydrogenase (LDH), and inflammatory factors interleukin-6 (IL-6) and interferon -γ (IFN-γ) between two groups of patients. Results Compared with the control group, the observation group had a shorter time in the symptom improvement and hospital stay. After treatment, the serum CRP, SF, LDH, IL-6, and IFN-γ levels in both groups were significantly decreased, and the observation group was lower than the control group, and the difference between two groups was statistical significance (P < 0.05). Conclusion Bronchoscopic alveolar lavage combined with levofloxacin can help alleviate the inflammatory response of children with severe mycoplasma pneumonia, improve clinical symptoms, accelerate treatment progress, and shorten hospital stay. This indicates that bronchoalveolar lavage with levofloxacin is a treatment method with definite efficacy and worthy of clinical promotion in children.